The effect of carvedilol on heart failure (HF) in patients with a functionally univentricular heart (UVH) remains unclear.
ince Waagstein et al first reported the use of β-blockers for the treatment of heart failure (HF) in 1975, 1 there has been increasing evidence that they improve the cardiac function and prolong survival in adult patients with HF. 2-4 Carvedilol especially, which is a nonselective β-blocker with additional vasodilatory properties, has been shown to reduce morbidity and mortality in adults with HF, 5-7 and is currently a first-line therapy for symptomatic HF in adults. 8, 9 The effectiveness of carvedilol in pediatric patients with dilated cardiomyopathy, ischemic heart disease, and congenital heart disease has been reported, 10-14 although another study failed to identify clinical effectiveness in children and adolescents with systolic HF. 15 To our knowledge, there are no reports describing the use of carvedilol for patients with a functionally univentricular heart (UVH), except for our previous case report. 16 In this study, we retrospectively evaluated the clinical effects of carvedilol for HF in patients with a UVH.
Methods

Patients
UVH in the present study included the following: single right ventricle (RV), single left ventricle (LV), tricuspid atresia, hypoplastic left heart syndrome, and complex heart diseases in which biventricular repair was not possible. Among patients admitted to hospital between 2002 and 2008, we identified 51 patients with UVH who were treated with carvedilol for HF. The anatomical diagnoses of these patients are shown in Table 1 .
The definition of HF was the presence of cardiac symptoms and moderately or severely reduced ventricular systolic function. Easy fatigability, dyspnea, and/or edema were the main cardiac symptoms. Systolic ventricular dysfunction was defined as an ejection fraction (EF) ≤50%, which was evaluated using 2-dimensional (D) echocardiography, in subjects in whom the anatomical LV was the main systemic chamber. In subjects in whom the RV was the main systemic chamber, systolic ventricular dysfunction was defined as the presence Carvedilol in the Univentricular Heart of qualitative evidence of a dilated ventricle with moderate to severe systemic ventricular systolic dysfunction, which was evaluated using 2-D echocardiography.
The indication of carvedilol was the presence of HF, defined as above, despite the use of diuretics, digoxin, and/or angiotensin-converting enzyme (ACE) inhibitors. Firstly, we analyzed the clinical data of all the patients before and after carvedilol administration. Secondly, we analyzed the clinical data for 3 groups (ie, after Fontan operation (group F, n=18), after bidirectional Glenn but before Fontan operation (group G, n=14), and after shunt or no operation (group NF, n=19)) because the hemodynamics before the Fontan operation and after the Glenn or Fontan operation are very different.
The dose of carvedilol varied according to each patient's condition, but it was basically increased to the maintenance dose within 3 months as follows: 0.05, 0.1, 0.2, 0.4, 0.6, and 0.8 mg · kg -1 · day -1 , with an increase every 2 weeks, unless HF deteriorated. The mean initial and maximum doses of carvedilol were 0.04±0.03 (0.01-0.18) and 0.42±0.29 (0.01-0.92) mg · kg -1 · day -1 , respectively. Follow-up reaching the maintenance dose is shown in Table 2 .
We compared baseline and post-treatment parameters to assess the effectiveness of carvedilol. The post-treatment parameters were obtained after reaching the maintenance dose and included the cardiothoracic ratio (CTR), ventricular end-diastolic pressure (EDP), central venous pressure (CVP), ventricular EF, systemic blood flow (Qs), ratio of pulmonary blood flow/systemic blood flow (Qp/Qs), serum brain natriuretic peptide level (BNP), and total dose of diuretic or furosemide. The EDP, CVP, EF, Qs, and Qp/Qs were measured at the time of cardiac catheterization. In patients who underwent cardiac catheterizations, the EF of the main ventricle was measured from cineangiograms using Simpson's rule. 3 We also evaluated the New York Heart Association (NYHA) functional class.
Statistical Analysis
Analysis was performed using statistical software (Excel Other includes complete atrioventricular septal defect (n=3), pulmonary atresia with intact ventricular septum (n=2), transposition of the great arteries (n=1), corrected transposition of the great arteries (n=1). UVH, functionally univentricular heart; F group, after Fontan operation; G group, after bidirectional Glenn but before Fontan; NF group, after shunt operation or no operation; y, years; m, months; SRV, single right ventricle; SLV, single left ventricle; DORV, double-outlet right ventricle; HLHS, hypoplastic left heart syndrome; TA, tricuspid atresia. 
Abbreviations see in Table 1 . 
Results
Carvedilol administration was discontinued in one patient at a dose of 0.064 mg · kg -1 · day -1 due to worsening HF, but the clinical parameters before stopping carvedilol were included in the analysis. None of the remaining patients experienced adverse effects requiring reduction in the carvedilol dose. The numbers of patients in whom we could obtain clinical parameters are shown in Table 3 . The CTR, EF, and dose of furosemide changed significantly (P<0.05) (Table 3, Figure) . The EDP, Qs, and CVP did not show significant changes. With in-group analysis, the EF improved in the F group from 35±15% (15-50%) to 45±10% (33-56%) (P<0.05), but remained unchanged in the G and NF groups. In the NF and G group (n=5), Qp/Qs before carvedilol (0.8±0.5) did not change significantly after carvedilol (1.1±0.5). The BNP improved only in the NF group from 697±639 to 373±514 pg/ml (P<0.05). The NYHA functional class, evaluated in 15 patients over 15 years of age, improved significantly (Table 4) .
The main ventricular chamber was the RV in 39 patients and the LV in 12 patients. The effect of ventricular morphology on the effectiveness of carvedilol was evaluated (Table 5) . Although CTR and EF improved only in patients with RV morphology, BNP improved only in patients with LV morphology.
The patients were receiving various combinations of medication (Table 6) . Before starting carvedilol, 41 patients received furosemide and 13 received hydrochlorothiazide. . EF before and after administration of carvedilol. *P<0.01. CTR, cardiothoracic ratio; EF, ejection fraction; F group, after Fontan operation; G group, after bidirectional Glenn but before Fontan; NF group, after shunt operation or no operation. Carvedilol in the Univentricular Heart
After treatment, furosemide and hydrochlorothiazide were completely discontinued in 6 and 10 patients, respectively. Five patients died during follow-up (2 patients in the G group and 3 in the NF group). In the first patient, we had started carvedilol after the Glenn procedure, but the patient died following total cavopulmonary connection (TCPC) completion due to postoperative infection. The second patient died after the Glenn procedure due to postoperative infection. In the third patient, carvedilol had to be discontinued due to renal failure caused by cyanotic nephropathy. In the fourth patient, we had started carvedilol following the initial Norwood operation, but the patient died of aggravating subsemilunar valve stenosis. The fifth patient died of bacterial endocarditis. None of these deaths was attributable to the side-effects of carvedilol.
Discussion
We have reported a previous case in which carvedilol was effective for HF that developed after the Fontan operation. 16 That patient had severe cardiac failure (NYHA class III), but underwent a successful TCPC conversion operation after improvement in cardiac function following carvedilol therapy. This experience prompted us to use carvedilol in a series of patients with UVH suffering from HF.
Beta-blockers have been shown to decrease mortality and morbidity in adult clinical trials, promising to markedly advance the treatment of HF. 17 They enhance ventricular remodeling, 18-20 decrease the levels of free radicals 21-23 and adverse neurohumoral factors, 24-27 decrease arrhythmia, and thus reduce HF symptoms. 9, [28] [29] [30] In this study, the CTR and EF were improved and the total dose of diuretics was decreased by carvedilol therapy. The EF particularly improved in the F group. When we focused on the group of patients ≥15 years, improvement in NYHA class was observed, although the mechanisms of this improvement remains unclear. In particular, the effect of carvedilol on diastolic ventricular function remains to be clarified. Table 1 . Table 3 . Cibenzoline succinateISHIBASHI N et al.
In the study by Shaddy et al 15 of pediatric patients in whom the main chamber was the LV, the LV shortening fraction increased in the placebo group, low-dose (0.2 mg/kg) carvedilol group, and high-dose (0.4 mg/kg) carvedilol group, but the increase was the greatest in the high-dose carvedilol group. Their study results suggested a beneficial trend in highdose carvedilol therapy in patients in whom the main chamber was the LV. In the present study, such dose dependency could not be analyzed because of the small number of patients. Patients in the other study consisted mainly of those with dilated cardiomyopathy, whereas we did not include such patients in the present study and the majority of patients had the RV as the main chamber. In the present study, the chamber-specific tendency was heterogeneous (Table 5) . Although CTR and EF improved only in patients with RV morphology, BNP improved only in patients with LV morphology. The reasons why the changes in parameters were not consistent in the present study remain unclear, but the different response to carvedilol by the 2 ventricles may be 1of the reasons. The present study, however, did show that carvedilol is effective in patients with the RV as the main chamber.
Serum BNP levels have shown by some to be useful for evaluating cardiac function in the UVH in some reports, 31-35 but not by others. 36 In the present study, the BNP level did not show a significant change in Fontan patients despite improvements in some of the clinical parameters. The reason for this remains unclear, and so future follow-up is necessary.
Study Limitations
Firstly, this study is a retrospective analysis of the effects of carvedilol for HF in patients with a UVH and therefore the degree of ventricular dysfunction was not identical among subjects. Secondly, systolic ventricular dysfunction was determined using echocardiography. Calculation of the EF of the RV from echocardiography in the UVH is difficult and therefore RV function was evaluated qualitatively. In previous studies investigating the effect of carvedilol in patients with cardiomyopathy and congenital heart diseases, including UVH, RV function was also evaluated in a similar fashion. 15,37 Thirdly, the subjects had heterogeneous diagnoses. Multiple operations were carried out over the course of carvedilol treatment, as is often required in patients with a UVH. These factors may have influenced cardiac function, aside from the pharmacological effects of carvedilol. In the present study, however, the effect of carvedilol was evaluated within the group before and after operations. Fourthly, the relationship between the dose of carvedilol and its effectiveness remains unclear. In the present study, post-treatment clinical parameters were obtained after reaching the maintenance dose because clinical evaluation during dose adjustment was difficult.
Conclusions
This study demonstrated that the addition of carvedilol to standard medical treatments such as diuretics, digoxin, and ACE inhibitor could reduce the symptoms of HF and improve clinical parameters in patients with a UVH. Multicenter, randomized, controlled, prospective trials are mandatory to further elucidate the effect of carvedilol in the treatment of HF in patients with a UVH.
